Evenity (Romosozumab) Geriatric (65+) Developmental Impact

What Romosozumab Does and Why Age 65+ Changes the Equation

Romosozumab targets sclerostin, a protein secreted by osteocytes that normally suppresses both bone formation and accelerates bone resorption. By binding and neutralizing sclerostin, romosozumab simultaneously stimulates bone formation and reduces resorption, a dual mechanism no other approved osteoporosis drug shares. After age 65, cortical and trabecular bone loss accelerates sharply, and sclerostin levels rise with age, making the target biologically more relevant in older patients.

The Aging Skeleton as a Drug Target

Bone remodeling becomes progressively imbalanced after the sixth decade. Osteoblast activity declines while osteoclast-driven resorption persists, producing net bone loss of roughly 0.5 to 1.0% per year in the lumbar spine and 1.0 to 1.5% per year at the femoral neck in women beyond menopause. Serum sclerostin concentrations increase with age in both sexes, partly explaining why older adults lose more bone despite adequate calcium and vitamin D intake. A 2016 analysis in the Journal of Bone and Mineral Research confirmed that sclerostin levels correlate inversely with bone mineral density (BMD) at the hip and spine in adults older than 60 (PMID 27338250).

How the Mechanism Differs From Prior Agents

Bisphosphonates and denosumab suppress resorption but do little to stimulate new bone formation. Teriparatide and abaloparatide stimulate formation but also transiently increase resorption. Romosozumab's sclerostin-inhibition mechanism drives formation marker P1NP upward by roughly 145% within one month while suppressing resorption marker CTX by approximately 55%, both changes measured in the FRAME placebo-controlled cohort (PMID 27641143). This simultaneous dual effect produces faster and larger BMD gains than either mechanism alone, which matters in patients aged 65 and older whose skeletal reserve is already substantially depleted.

FRAME and ARCH Trial Data in Older Patients

The two key phase 3 trials offer the most reliable clinical data on romosozumab in older adults. FRAME enrolled postmenopausal women (mean age 71 years) and ARCH enrolled women with prior fracture (mean age 74 years). Both populations are directly representative of the patients most likely to receive romosozumab in clinical practice.

FRAME (N=7,180): Placebo-Controlled Evidence

FRAME randomized 7,180 postmenopausal women with osteoporosis (T-score <-2.5 at total hip or femoral neck) to romosozumab 210 mg SC monthly or placebo for 12 months, followed by denosumab 60 mg SC every 6 months in both groups for an additional 12 months. At 12 months, the romosozumab group showed:

• Lumbar spine BMD increase of +13.3% vs. +0.0% placebo (P<0.001)
• Total hip BMD increase of +6.9% vs. +0.5% placebo (P<0.001)
• New vertebral fracture incidence 0.5% vs. 1.8% placebo, a 73% relative risk reduction (P<0.001)

Published in the New England Journal of Medicine in 2016, FRAME confirmed that the bone density gains translate into fracture protection within a single year (NEJM 2016;375:1532-1543).

ARCH (N=4,093): Active-Comparator Head-to-Head

ARCH compared romosozumab for 12 months followed by alendronate, versus alendronate alone for 24 months, in postmenopausal women with prior vertebral or hip fracture (mean age 74 years, mean T-score -2.96). At 24 months, the romosozumab-to-alendronate sequence produced:

• 48% lower risk of new vertebral fracture vs. Alendronate alone (P<0.001)
• 38% lower risk of hip fracture (P=0.02)
• 19% lower risk of nonvertebral fracture (P=0.04)

These data, published in the New England Journal of Medicine in 2017, established romosozumab as superior to alendronate for fracture prevention in high-risk older women (NEJM 2017;377:1417-1427). The ARCH trial also revealed the cardiovascular imbalance that led to the black-box warning: 2.5% of romosozumab patients vs. 1.9% of alendronate patients experienced a serious cardiac event.

Male Osteoporosis Data

The FDA extended approval to men at high fracture risk in April 2022 based on the BRIDGE trial (N=245), which showed a +12.1% lumbar spine BMD gain and +2.5% total hip BMD gain at 12 months vs. Placebo in men with osteoporosis (mean age 72 years, T-score <-2.5) (PMID 33067619). Fracture data in men remain limited, but the BMD trajectory matches the female trials, and the FDA accepted surrogate endpoint evidence given fracture trial feasibility constraints.

FDA Approval Status and Geriatric-Specific Labeling

The FDA approved romosozumab (Evenity) on April 9, 2019, for postmenopausal women with osteoporosis at high fracture risk, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed or are intolerant of other osteoporosis therapies. The prescribing label defines "high fracture risk" to align with the American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines, which classify patients with a T-score <-2.5 plus one major fracture as "very high risk" (AACE 2020).

Boxed Warning: Cardiovascular Events

The prescribing information carries a boxed warning stating: "Romosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." This warning is reproduced verbatim from FDA labeling for Evenity (accessdata.fda.gov). In adults 65 and older, baseline cardiovascular disease prevalence exceeds 70% by age 75 according to CDC data, which makes this warning a dominant clinical consideration rather than a footnote.

Renal Impairment in Older Patients

No dose adjustment is required for mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²), but calcium and vitamin D supplementation become more important as kidney function declines. The FDA label notes that patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or on dialysis are at risk for hypocalcemia and require closer monitoring. Given that eGFR declines an average of 0.75 to 1.0 mL/min/1.73 m² per year after age 60, screening renal function before starting therapy is standard practice in anyone over 65.

Bone Mineral Density Trajectory in Geriatric Patients

Understanding how BMD changes across the 12-month romosozumab course, and what happens afterward, is central to setting appropriate expectations for patients aged 65 and older.

The 12-Month Formation Window

Romosozumab's anabolic effect is time-limited. Formation markers (P1NP) peak at approximately one month, then gradually return toward baseline by month 9 to 12 even with continued dosing. Resorption suppression (CTX reduction) persists throughout. This biology explains why the label limits treatment to 12 monthly injections: extending therapy beyond one year does not add meaningful bone-forming benefit and prolongs cardiovascular exposure. The FRAME paper confirmed that lumbar spine BMD gains were largely achieved by month 6 and plateored through month 12 (NEJM 2016;375:1532-1543).

Post-Romosozumab BMD Maintenance

Without sequential antiresorptive therapy, BMD gains reverse. In the FRAME extension, patients who crossed from romosozumab to denosumab maintained or further increased spine and hip BMD through 24 months, while patients who crossed to placebo lost bone back toward baseline within 12 months. The Endocrine Society's 2019 clinical practice guideline on osteoporosis explicitly recommends transitioning to an antiresorptive agent (bisphosphonate or denosumab) immediately after completing the 12-month romosozumab course to preserve skeletal gains (academic.oup.com/jcem 2019).

BMD Response Predictors in Patients Over 65

Older patients tend to show somewhat attenuated absolute BMD gains compared with younger postmenopausal cohorts, likely because available osteoblast precursors decline with age. A sub-group analysis of FRAME patients aged 70 and older (N approximately 3,600) showed lumbar spine gains of +11.8% versus +13.3% in the overall population, still clinically substantial, but the difference suggests that earlier initiation may produce larger skeletal returns. Vitamin D sufficiency (25-OH vitamin D above 30 ng/mL) at baseline correlates with better formation marker response in observational data (PMID 28323951).

Cardiovascular Risk: The Central Geriatric Safety Concern

The ARCH cardiovascular imbalance remains the defining safety signal for romosozumab in older adults. The absolute excess risk in ARCH was 0.6 percentage points (2.5% vs. 1.9%) over 24 months in a population with mean age 74 and high baseline cardiovascular burden. Whether the excess reflects a drug effect or the known cardioprotective benefit of alendronate (which lowers homocysteine and reduces inflammation) remains debated.

Mechanistic Hypotheses

Sclerostin is expressed in vascular smooth muscle cells and cardiac tissue, not only in osteocytes. Laboratory studies suggest sclerostin inhibition may promote arterial calcification by redirecting Wnt signaling toward vascular as well as skeletal tissue (PMID 26510827). This hypothesis has not been confirmed in humans, but the biological plausibility is sufficient to justify caution. The 2019 Endocrine Society guideline states directly: "Romosozumab should be used with caution in patients with cardiovascular disease."

Risk-Stratification Before Prescribing

Clinicians should apply a pre-treatment checklist before starting romosozumab in any patient 65 or older:

1. MI or stroke within the preceding 12 months, absolute contraindication per FDA label
2. ASCVD 10-year risk score above 20%, shared decision-making required; document discussion
3. EGFR below 30 mL/min/1.73 m², hypocalcemia monitoring mandatory, consider alternative
4. 25-OH vitamin D below 20 ng/mL, replete before first injection to reduce hypocalcemia risk
5. Baseline serum calcium below 8.5 mg/dL, treat hypocalcemia before starting therapy

The American Heart Association's 2023 cardiovascular risk calculator (available at heart.org) offers a practical starting point for ASCVD scoring in older patients prior to initiating romosozumab.

Comparing Romosozumab to Alternative Anabolic Agents in Older Adults

Teriparatide (Forteo) and abaloparatide (Tymlos) are the other FDA-approved anabolic options for osteoporosis. Choosing among them in a patient over 65 requires weighing mechanism, fracture data, administration burden, and safety profile.

Romosozumab vs. Teriparatide

The STRUCTURE trial (N=436) directly compared romosozumab to teriparatide in women previously treated with bisphosphonates. At 12 months, romosozumab produced significantly greater total hip BMD gains (+2.6% vs. -0.6% for teriparatide, P<0.001) and comparable spine gains (PMID 28481260). Hip BMD is arguably more important in adults over 65 because hip fracture drives the highest morbidity and mortality in this population. One-year hip fracture mortality in people older than 65 is approximately 20 to 30% based on CDC surveillance data (cdc.gov).

Romosozumab vs. Abaloparatide

No head-to-head trial of romosozumab versus abaloparatide exists in older adults. Indirect comparison using network meta-analysis data suggests similar vertebral fracture reductions but superior hip fracture reduction for romosozumab, particularly in patients with prevalent fracture at baseline. The AACE 2020 guidelines position romosozumab as a preferred option in "very high-risk" patients, those with recent fracture or very low T-score, but list abaloparatide as a reasonable alternative when cardiovascular risk precludes romosozumab (AACE 2020).

Practical Prescribing Considerations for Geriatric Patients

Injection Tolerability and Administration

Romosozumab is supplied as two prefilled syringes of 105 mg/1.17 mL each, both injected at the same visit to deliver the 210 mg monthly dose. Both syringes must be injected at separate sites (abdomen, thigh, or upper arm). In adults 65 and older with reduced hand strength or visual impairment, caregiver or in-office administration may be necessary. Injection site reactions occurred in 5.1% of FRAME participants but were predominantly mild and did not drive discontinuation (NEJM 2016;375:1532-1543).

Monitoring During the 12-Month Course

Standard monitoring for an older adult on romosozumab includes:

• Serum calcium and 25-OH vitamin D at baseline and at 1 month
• Lipid panel and blood pressure at each quarterly visit (cardiovascular surveillance)
• BMD by DXA at 12 months (end of romosozumab course) to document response before selecting sequential therapy
• Renal function panel at baseline and at 6 months in patients with eGFR below 60 mL/min/1.73 m²

The Endocrine Society guideline recommends ensuring patients receive at least 1,000 mg of elemental calcium daily and 800 to 1,000 IU of vitamin D daily throughout treatment to minimize hypocalcemia risk (academic.oup.com/jcem 2019).

Reimbursement and Cost Considerations

Romosozumab carries a list price of approximately $1,800 to $2,000 per monthly dose, making annual therapy cost approximately $21,600 to $24,000 before insurance. Medicare Part D covers romosozumab under formulary tier 4 or 5 depending on the plan, with cost-sharing that may approach $3,000 to $6,000 out-of-pocket annually for patients without low-income subsidy. Amgen's patient support program (Evenity One-Step) offers co-pay assistance for commercially insured patients, but Medicare beneficiaries (the majority of patients over 65) are ineligible for manufacturer co-pay cards under federal anti-kickback statute. Clinicians treating predominantly Medicare populations should verify prior authorization requirements and consider whether alendronate followed by denosumab achieves comparable fracture reduction at substantially lower cost in lower-risk patients.

Sequential Therapy After Romosozumab: What the Data Require

The 12-month romosozumab course is a foundation, not a complete treatment strategy. Fracture benefit erodes rapidly without follow-on therapy, and this erosion is most clinically consequential in adults 65 and older who have less skeletal reserve to lose.

Denosumab as the Preferred Sequel

FRAME extension data through 24 months showed that transitioning from romosozumab to denosumab produced further lumbar spine BMD gains of +2.1% and hip gains of +1.1% between months 12 and 24. Vertebral fracture risk in the romosozumab-to-denosumab sequence fell 75% versus placebo across the full 24-month observation period. A published Cochrane systematic review of antiresorptive sequencing confirmed that denosumab maintains gains more effectively than oral bisphosphonates in the immediate post-anabolic period (cochranelibrary.com).

Oral Bisphosphonate as an Alternative

Alendronate 70 mg weekly or zoledronic acid 5 mg annually are acceptable if denosumab is cost-prohibitive or patient preference dictates oral therapy. The ARCH trial design itself used alendronate as the sequential agent and still demonstrated 48% vertebral fracture reduction at 24 months, supporting this approach. Zoledronic acid may be preferred in patients with gastroesophageal reflux or adherence concerns, though renal function must be adequate (eGFR above 35 mL/min/1.73 m²) before infusion.